Ph.D., CEO and Co-Founder, InterOme
Biography
Dr. Corina J Shtir holds a Ph.D. from the University of Southern California in Biostatistics with applications in Statistical Genetics and Epidemiology, a postdoctoral degree in neuroscience from the University of California Los Angeles, and a second postdoctoral degree in statistical genetics applied in diabetes at Cambridge, UK. Prior to her current role, Dr. Shtir was Global VP and Head of Precision Medicine at Thermo Fisher Scientific, where she led the growth of Thermo Fishers Precision Medicine segment into an operation encompassing more than 200 large or nationalscale programs, with a presence in 100+ countries. Dr. Shtir drives new business, strategy, and product development, expanding InterOmes global reach through multidisciplinary collaborations, joint ventures, and external partnerships.
Talk
Clinical & Research Tools Showcase:
InterOme Inc
InterOme is a digital health company that combines >30 years of experience in public health and precision medicine, custom software development, management services, and large-scale system integration. We solve general systemic problems through highly specialized approaches and deploy single-user applications up to enterprise-wide business systems.
Rapid Operationalization of Environmental & Biothreat Surveillance
InterOme provides digital and industry framework to assess and evaluate public health through integrative and automated operations.
Session Abstract – PMWC 2023 Silicon Valley
Showcase Track S2 - January 25 2.45 P.M.-4.00 P.M.,Showcase Track S2 - January 26 1.30 P.M.-4.00 P.M.,Showcase Track S2 - January 27 1.15 P.M.-1.30 P.M.
The PMWC 2023 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
